Trial Profile
A Phase 1, Randomized, Partially Blinded, Placebo and Positive Controlled, 3-Period, Six-Sequence, Single and Multiple-Dose Cross-Over Study to Assess the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 01 Nov 2017 New trial record